Helius Therapeutics, a leader in New Zealand’s medicinal cannabis industry, is excited to announce a strategic partnership with Balancial Denmark, a key player in the Danish pharmaceutical market, to launch Helius Therapeutics’ premium medicinal cannabis extracts in Denmark. This marks the debut of these high-quality New Zealand-grown and -made products in the Danish market. This collaboration merges Helius Therapeutics’ advanced cannabis cultivation and extraction expertise with Balancial Denmark’s strong local presence to address the increasing demand for medicinal cannabis in Denmark. The introduction of these extracts aims to provide Danish patients with a new, effective treatment option.
Regulatory Standards and Market Context
Medicinal cannabis in New Zealand has been regulated since the launch of the Medicinal Cannabis Scheme in April 2020. This scheme ensures that all products meet stringent safety, quality, and efficacy standards. Helius Therapeutics, which began its operations in the New Zealand market in 2021, is committed to upholding these rigorous standards to deliver premium products.
Denmark’s medicinal cannabis program, introduced in January 2018, provides patients with access to regulated, high-quality cannabis-based treatments. Currently, approximately 10,000 patients in Denmark benefit from medicinal cannabis, highlighting the growing need and acceptance of these treatments.
Carmen Doran, CEO of Helius Therapeutics, commented, “Our partnership with Balancial Denmark is a significant milestone in our mission to broaden access to high-quality medicinal cannabis. We are confident that our New Zealand-grown extracts will meet the high standards expected in the Danish market and positively impact patient care.”
Bo Tandrup, Managing Director of Balancial Denmark, added, “We are delighted to collaborate with Helius Therapeutics to introduce their medicinal cannabis extracts to Denmark. This partnership underscores our dedication to providing advanced treatment solutions while adhering to the highest regulatory standards.”
As part of the partnership, both companies are committed to delivering comprehensive educational support to healthcare professionals. This includes providing detailed product information, best practices for patient management, and ongoing training to ensure effective integration of medicinal cannabis into treatment plans. The goal is to equip healthcare providers with the knowledge and resources necessary to offer informed guidance and optimize patient outcomes.
For more information about the partnership, please contact:**Media Inquiries:**Carmen Doran CEO, Helius Therapeutics Email: carmen.doran@helius.co.nz
About Helius Therapeutics:
Helius Therapeutics, launched in the New Zealand market in 2021, is a leading innovator in medicinal cannabis. The company is dedicated to providing high-quality, safe, and effective therapeutic solutions, adhering to stringent regulatory standards to ensure optimal patient outcomes.
About Balancial Denmark:
Balancial Denmark is a prominent pharmaceutical company in Denmark, known for its expertise in delivering advanced therapeutic solutions. With a focus on regulatory excellence and patient care, Balancial Denmark is committed to enhancing healthcare outcomes in Denmark.
Comments